Evidence map›Paper›PMID 32514854›Full record

ArticleZeitschrift fur Rheumatologie2020

[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].

N Steinchen, U Müller-Ladner, U Lange

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

N SteinchenRheumatologie Kassel, Kassel, Deutschland.
U Müller-LadnerAbteilung Rheumatologie, klinische Immunologie, Osteologie, Physikalische Medizin, Campus Kerckhoff Universität Gießen, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland.
U LangeAbteilung Rheumatologie, klinische Immunologie, Osteologie, Physikalische Medizin, Campus Kerckhoff Universität Gießen, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland. U.Lange@kerckhoff-klinik.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A case with rheumatoid arthritis and insufficient compensation under disease-modifying combined long-term therapy with methotrexate and leflunomide is reported. After recovery from a COVID-19 infection, a tumor necrosis factor (TNF) inhibitor therapy was initiated. Until now no reactivation of the COVID-19 infection with positive SARS-CoV‑2 antibody status has occurred.

Indexed as

Biological TherapyAntibodies, ViralArthritis, RheumatoidBetacoronavirusCoronavirus InfectionsCOVID-19HumansLeflunomideMethotrexatePandemicsPneumonia, ViralSARS-CoV-2Tumor Necrosis Factor InhibitorsVirus ActivationAntibodies, ViralLeflunomideMethotrexateTumor Necrosis Factor InhibitorsBiological therapyCOVID-19 infectionImmunsuppressionPositive antibody status SARS-CoV2Rheumatoid arthritis

Identifiers

PMID32514854
PMCPMC7278764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.